Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma

The combination of CTLA-4 blockade ipilimumab (Ipi) with VEGF-A blocking antibody bevacizumab (Bev) has demonstrated favorable clinical outcomes in patients with advanced melanoma. Galectin-3 (Gal-3) plays a prominent role in tumor growth, metastasis, angiogenesis, and immune evasion. Here we report...

Full description

Bibliographic Details
Main Authors: Xinqi Wu, Anita Giobbie-Hurder, Erin M. Connolly, Jingjing Li, Xiaoyun Liao, Mariano Severgnini, Jun Zhou, Scott Rodig, F. Stephen Hodi
Format: Article
Language:English
Published: Taylor & Francis Group 2018-07-01
Series:OncoImmunology
Subjects:
antibody responses to galectin-3
anti-vegf
immune therapy
galectin-3
melanoma
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1440930

Internet

http://dx.doi.org/10.1080/2162402X.2018.1440930

Similar Items